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Abstract: Background and Aims: n-3 polyunsaturated fatty acid (PUFA) 
treatment may decrease liver fat in non-alcoholic fatty liver disease 
(NAFLD), but uncertainty exists whether this treatment also decreases 
cardiovascular disease (CVD) risk in NAFLD. We tested whether 15-18 
months n-3 PUFA [docosahexaenoic acid (DHA) and eicosapentaenoic acid] 
(Omacor/Lovaza, 4g/day) vs placebo decreased carotid intima-media 
thickness (CIMT) progression, a surrogate marker of CVD risk. We also 
evaluated if improvement in markers of NAFLD severity was associated with 
decreased CIMT progression over time. 
Methods: In a pre-specified sub-study of the WELCOME (Wessex Evaluation 
of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy) 
trial (NCT00760513), CIMT was measured using B-mode ultrasound while 
NAFLD severity was assessed by measuring liver fat percentage (magnetic 
resonance spectroscopy) and hepatic necro-inflammation (serum 
cytokeratin-18 (CK-18) concentration), at baseline and end of study. 
Results: 92 patients (age 51.5±10.7 years, 57.6% men) completed the 
study. In the treatment group (n=45), CIMT progressed by 0.012mm (IQR 
0.005-0.020mm) compared to 0.015mm (IQR 0.007-0.025mm) in the placebo 
group (n=47) (p=0.17). Reduced CIMT progression in the entire cohort was 
independently associated with decreased liver fat (standardized β-
coefficient 0.32, p=0.005), reduced CK-18 levels (standardized β-
coefficient 0.22, p=0.04) and antihypertensive usage (standardized β-
coefficient -0.31, p=0.009) in multivariable regression analysis after 
adjusting for all potential confounders. Decreased weight (standardized 
β-coefficient 0.30, p<0.001) and increased DHA tissue enrichment during 
the 18-month study (standardized β-coefficient -0.19, p=0.027) were both 
independently associated with decreased liver fat, but not with CK-18.  
Conclusion: Improvement in two markers of NAFLD severity is independently 
associated with reduced CIMT progression. 
  
 
 
Highlights 
 
 We studied the effects of high-dose n-3 PUFA vs placebo on CIMT 
progression over 18 months 
 We also analysed the association between biomarkers of NAFLD severity and 
CIMT progression 
 No significant effect of n-3 PUFA vs placebo on altering CIMT progression 
 Reduced CIMT progression was independently associated with decreased liver 
fat and reduced CK-18 levels over 18 months 
 
Highlights (for review)
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Improvement in non-alcoholic fatty liver disease 
severity is associated with a reduction in carotid 
intima-media thickness progression 
 
Lokpal Bhatia MB BCh
a,b,c
, Eleonora Scorletti MD
a,b
, Nicholas Curzen PhD
b,c
, 
Geraldine F. Clough PhD
a,b
, Philip C. Calder PhD
a,b 
and Christopher D. Byrne PhD
a,b
 
 
a
Human Development and Health Academic Unit, Faculty of Medicine, University of 
Southampton, Southampton, UK 
b
National Institute for Health Research Southampton Biomedical Research Centre, 
University of Southampton and University Hospital Southampton NHS Foundation 
Trust, Southampton, UK 
c
Wessex Cardiac Centre, University Hospital Southampton NHS Foundation Trust, 
Southampton, UK 
 
Corresponding author:  
Dr Lokpal Bhatia BSc(Hons), MB BCh,  
Cardiologist & Clinical Research Fellow 
Human Development and Health Academic Unit 
University of Southampton 
IDS Building 
MP 887 Southampton General Hospital 
Tremona Road 
Southampton SO16 6YD 
United Kingdom 
Tel: +447977139731 
Email: lokebhatia@aol.com 
 
Keywords: carotid intima-media thickness; non-alcoholic fatty liver disease; fatty 
acids, Omega-3; cardiovascular disease; atherosclerosis 
 
Word count: 3978 
 
No. of tables: 3 
No. of figures: 2 
No. of supplementary figures: 1 
No. of supplementary tables: 1 
 
 
 
 
 
 
 
 
*Abstract, Title Page, Manuscript, References, Legends
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Abstract 
 
Background and Aims: n-3 polyunsaturated fatty acid (PUFA) treatment may 
decrease liver fat in non-alcoholic fatty liver disease (NAFLD), but uncertainty exists 
whether this treatment also decreases cardiovascular disease (CVD) risk in NAFLD. 
We tested whether 15-18 months n-3 PUFA [docosahexaenoic acid (DHA) and 
eicosapentaenoic acid] (Omacor/Lovaza, 4g/day) vs placebo decreased carotid intima-
media thickness (CIMT) progression, a surrogate marker of CVD risk. We also 
evaluated if improvement in markers of NAFLD severity was associated with 
decreased CIMT progression over time. 
Methods: In a pre-specified sub-study of the WELCOME (Wessex Evaluation of 
fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy) trial 
(NCT00760513), CIMT was measured using B-mode ultrasound while NAFLD 
severity was assessed by measuring liver fat percentage (magnetic resonance 
spectroscopy) and hepatic necro-inflammation (serum cytokeratin-18 (CK-18) 
concentration), at baseline and end of study. 
Results: 92 patients (age 51.5±10.7 years, 57.6% men) completed the study. In the 
treatment group (n=45), CIMT progressed by 0.012mm (IQR 0.005-0.020mm) 
compared to 0.015mm (IQR 0.007-0.025mm) in the placebo group (n=47) (p=0.17). 
Reduced CIMT progression in the entire cohort was independently associated with 
decreased liver fat (standardized β-coefficient 0.32, p=0.005), reduced CK-18 levels 
(standardized β-coefficient 0.22, p=0.04) and antihypertensive usage (standardized β-
coefficient -0.31, p=0.009) in multivariable regression analysis after adjusting for all 
potential confounders. Decreased weight (standardized β-coefficient 0.30, p<0.001) 
and increased DHA tissue enrichment during the 18-month study (standardized β-
coefficient -0.19, p=0.027) were both independently associated with decreased liver 
fat, but not with CK-18.  
Conclusion: Improvement in two markers of NAFLD severity is independently 
associated with reduced CIMT progression. 
 
 
Introduction 
 
Non-alcoholic fatty liver disease (NAFLD) is a common condition associated with 
obesity and type 2 diabetes, and is prevalent in up to a third of the general 
population.
1
 Current evidence demonstrates a robust association between NAFLD and 
atherosclerotic disease such that, for example, cardiovascular (CV) mortality 
represents the main mode of death in NAFLD and is also linked to the severity of 
liver disease.
2
 This progressive disease spectrum ranges from simple hepatic steatosis 
to varying grades of non-alcoholic steatohepatitis (NASH) and ultimately cirrhosis. 
Carotid intima-media thickness (IMT) is a well-established marker of subclinical 
atherosclerosis and is predictive of subsequent CV events in asymptomatic subjects.
3
 
Measurement of carotid IMT progression is commonly used in intervention trials as a 
surrogate end-point for adverse clinical events, as well as evaluating efficacy of 
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specific atherosclerotic-modifying therapies.
4
 Importantly, carotid IMT offers good 
inter-scan as well as good inter- and intra-observer reproducibility with intra-class 
correlation coefficients greater than 0.90 in previous trials utilising carotid IMT 
progression as a primary end-point.
5
 Although NAFLD is described as an independent 
risk factor for increased carotid IMT,
6
 no studies to date have investigated whether a 
reduction in the degree of fatty liver disease is associated with modification of carotid 
IMT progression. Our group recently described a significant reduction in liver fat 
percentage after 18 months treatment with high-dose n-3 polyunsaturated fatty acids 
(PUFAs) i.e. docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) 
(Omacor/Lovaza 4 g/day) versus placebo in subjects with a high level of erythrocyte 
DHA enrichment.
7
 Furthermore, studies from other groups have shown a positive 
association between high dietary intake of n-3 PUFAs and less carotid atherosclerotic 
plaque burden,
8
 as well as a plaque-stabilizing effect on carotid atheroma and 
improved arterial elasticity with n-3 PUFA treatment.
9, 10
  
The aims of this prespecified substudy of the WELCOME (Wessex Evaluation of 
fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy) trial
11
 
were: (i) to investigate the effects of high-dose n-3 PUFA treatment over 18 months 
on carotid IMT progression in NAFLD subjects and (ii) to describe associations 
between changes in markers of NAFLD disease severity (both in terms of simple 
steatosis and steatohepatitis) and carotid IMT progression over that time period. 
 
Material and Methods 
 
Subjects & Study design 
The present study included participants from the WELCOME study, which was a 
phase IV randomised, double-blind, placebo-controlled clinical trial undertaken in 
asymptomatic patients with NAFLD testing the effects of 15-18 months treatment 
with high-dose (3.6 g/day) purified ω-3 polyunsaturated fatty acids (PUFA) 
comprising DHA (46%) and EPA (38%) (Omacor 4 g/day; Pronova Biopharma ASA, 
Lysaker, Norway; Abbott Laboratories, Southampton, UK) on improving liver fat 
and/or fibrosis markers as its primary outcome (www.clinicaltrials.gov 
NCT00760513). The design and rationale for the WELCOME study have been 
reported previously.
11
 Briefly, subjects were included if they had recent imaging 
evidence of liver fat (ultrasound, magnetic resonance imaging or computerised 
tomography scan) and/or histological confirmation of NAFLD as well as exclusion of 
all other liver conditions causing liver fat accumulation such as excess alcohol intake 
or evidence of cirrhosis. The study was approved by the Southampton and South West 
Hampshire NHS Ethics Committee and all participants gave their written informed 
consent.  
103 participants were randomised (Fig. 1) to either Omacor 4g/day (n=51) or placebo 
(olive oil capsules, n=52) in a 1:1 double-blind fashion, with treatment duration of 
between 15-18 months. Compliance with the allocated medication was monitored by 
recording returned capsules at fixed intervals during the study. We also assessed 
erythrocyte EPA and DHA enrichment (between baseline and end of study) by gas 
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chromatography
11
 to test adherence to the intervention in the DHA+EPA group and to 
monitor dietary contamination with DHA and EPA in the placebo group. Dietary and 
lifestyle changes had already been recommended to all participants as part of their 
routine clinical care
12
 and this was continued throughout the study. There were no 
additional specific weight-loss programs or strict dietary restrictions placed on the 
participants as part of the study. 
 
Figure 1. Consort diagram showing recruitment for the WELCOME sub-study 
and the numbers of participants available for carotid analysis to test the effects 
of the intervention. For the reasons for withdrawal from the study, see 
supplementary Appendix 1 (end of text). 
 
 
 
Laboratory and anthropometry measurements 
Blood samples were drawn after an overnight fast (>12 hours) and serum was 
separated within 1 hour to undergo routine biochemical assay by conventional 
enzymatic methods (lipids, glucose, liver transaminases). Plasma and serum samples 
were also frozen at -70°C for further analysis in batches (insulin and cytokeratin-18 
(CK-18) subfraction M65 measured by M65 EpiDeath enzyme-linked immunosorbent 
assay kit (PEVIVA, Bromma, Sweden). CK-18 is a major intermediate filament 
protein in hepatocytes, which is released into the extracellular compartment following 
epithelial cell death. M65 levels not only reflect hepatocellular apoptosis and necrosis 
consistent with changes seen in NASH, but they have also been shown to correlate 
with fibrosis progression.
13
 
People identified who declined  (n = 72)  
Participants consented (n = 106) 
Participants withdrawing after consent (n=1) 
Participants who completed baseline visits (n = 105) 
Participant withdrawing after the baseline visits (n = 2) 
Potential participants identified (n = 178) 
Participants withdrawing during the study (n=8) 
Participants who completed end of study visits (n = 95) 
 
 
Participants randomised (n = 103) 
Participants allocated to Omacor (n=51) Participants allocated to placebo (n=52) 
Completed participants allocated to Omacor (n=45) Completed participants allocated to placebo (n=47) 
Carotid analysis measurements available (n=92) 
Inadequate carotid data for analysis (see text) (n=3) 
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Blood pressure was measured using a Marquette Dash 3000 monitor (GE Healthcare, 
Bucks, UK) on the non-dominant arm in the supine position after a minimum of 60 
minutes rest and a mean of 3 measurements 5 minutes apart was taken. Body mass 
index (BMI) was calculated as weight (kg) divided by the square of height (m). 
 
Liver fat assessment 
Magnetic resonance spectroscopy (MRS) is a quick and safe, non-invasive tool to 
accurately quantify liver fat in NAFLD and correlates well with liver biopsy results. 
Due to its high sensitivity, it can detect small percentage differences in liver fat 
accumulation in NAFLD.
14
 The full methodology of our MRS technique has already 
been described.
11
 Briefly, subjects had liver MRS scans at the start and end of the 
study. Three 20 x 20 x 20mm
3
 spectroscopic volumes of interest (VOI) were 
positioned in three standard areas of the liver and the average of each VOI’s lipid 
spectroscopic peak was used to calculate the percentage liver fat. VOIs remained 
constant for end of study measurements.  
 
Carotid ultrasonography 
The carotid arteries were studied with a duplex scanner using a 7.5 MHz linear array 
transducer (Philips IE33, Koninklijke Philips N.V., Netherlands) with ECG 
monitoring. Ultrasound parameters (dynamic range, depth range, power output and 
greyscale) for B-Mode carotid imaging were adjusted during image acquisition to 
optimize image quality. All scans were carried out according to a standardized 
protocol.
15
 Briefly, subjects lay supine with the neck slightly rotated and a transverse 
scan was first performed as a screening measure and also to identify the carotid 
bifurcation. Longitudinal images of the near and far walls of the common, proximal 
portion of the internal and external carotid arteries and the carotid bifurcation were 
examined and multiple images of 4 cine-loop cycles of the carotid artery were 
recorded and stored digitally for subsequent off-line analysis using Philips Q-Lab 
version 8 software (Koninklijke Philips N.V., Netherlands). For each subject, a 10 
mm plaque-free segment of IMT at the far wall of the common carotid artery 
immediately proximal to the carotid bulb was measured at ECG-gated end-diastole 
using QLAB automated software. An average of three different cardiac cycle 
measurements of IMT from each of the left and right common carotid arteries was 
calculated. The presence of carotid plaque at the distal common carotid, carotid bulb 
and proximal internal carotid arteries was also recorded.
15
 All measurements were 
performed and analysed off-line by a single trained operator blinded to subject 
treatment allocation. A random sample of 36 scans (baseline and end-of-study) 
underwent repeat analysis at a later date to test intraobserver reproducibility and the 
coefficient of variation was 2.8%, which is within the limit of 6% recommended by 
the American Society of Echocardiography.
15
 
 
Statistical analysis 
Statistical analysis was carried out with SPSS Version 21 (SPSS, Inc., Chicago, IL.) 
Mean values and standard deviations were calculated for continuous variables, or 
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median and interquartile range values for non-normally distributed variables. 
Univariate comparisons of normally distributed data were performed with 
independent Student’s t-tests. Mann-Whitney U or Wilcoxon signed rank tests were 
used for non-parametric data and Chi-squared tests for binary data. Pearson and 
Spearman correlations were used for normal and non-normally distributed data 
respectively. Log transformation was undertaken for non-normal variables where 
necessary. Exposure variables which showed a significant univariate association with 
the outcome variable, as well as key baseline variables that might confound the 
association between exposures and the outcome of interest were included in the 
multivariable stepwise regression model. A “difference” variable, which represented 
the arithmetic difference between the measurement at the end of the study minus the 
baseline measurement, was calculated for key exposures and potential confounders. 
All comparisons were two-sided and a p-value of < 0.05 was considered to be 
statistically significant. 
 
Results 
 
Data from 47 participants randomized to placebo and 45 randomized to DHA+EPA 
treatment was available for analysis out of n=103. Eight participants did not complete 
the study and a further three were excluded from the carotid analysis due to 
inadequate carotid data (one subject had images corrupted during transfer offline) or 
unsuitable images for adequate analysis (one had poor imaging quality and another 
had untreated familial hyperlipidaemia with significant widespread carotid plaque 
disease). From capsule counts at 6, 12 and 18 months, we estimated that all 
participants consumed >50% of their study medication and 78% consumed >75%. 
There were no serious adverse events attributable to study drugs. All participants 
consumed less than 21 units of alcohol per week at randomization apart from 1 
volunteer who drank 25 units/week, with no significant difference between groups 
(p=0.33). Alcohol consumption was also not associated with baseline liver fat 
(p=0.45) and did not vary significantly for each subject at the end of the study 
(p=0.92). The baseline characteristics of the participants according to randomization 
group are shown in Table 1. 
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Table 1. Baseline characteristics of participants in placebo and DHA+EPA 
groups at randomization 
 
 Placebo 
(n=47) 
DHA + EPA 
(n=45) 
p-value 
 
 
Age (years) 54.2 ± 9.4 48.6 ± 11.2 0.09 
 
Male/Female 31/16 22/23 0.10 
 
Diabetes (%) 34.0 35.6 0.88 
 
Dietary control (%) 4.3 2.1 0.56 
    
Oral anti-diabetic (%) 19.1 26.7 0.51 
 
Insulin use (%) 10.6 6.7 0.48 
    
Hypertension (%) 48.9 53.3 0.67 
 
Smoker (%) 10.6 11.1 0.94 
 
Ex-smoker (%) 36.2 31.1 0.59 
 
Antihypertensive use (%) 36.2 40.0 0.71 
 
Statin use (%) 46.8 40.0 0.51 
 
Total cholesterol (mmol/L) 4.72 ± 1.10 5.05 ± 1.19 0.17 
 
Low density lipoprotein 
cholesterol (mmol/L) 
2.77 ± 0.83 2.99 ± 0.99 0.29 
 
 
High density lipoprotein 
cholesterol (mmol/L) 
1.11 ± 0.26 1.02 ± 0.27 0.12 
 
 
Serum triglycerides (mmol/L) 1.4 (1.1, 2.0) 1.8 (1.4, 2.6) 0.03 
 
Fasting glucose (mmol/L) 5.4 (5.1, 6.9) 5.5 (4.9, 6.2) 0.37 
 
Haemoglobin A1c (% total Hb) 6.1 (5.7, 7.3) 5.9 (5.5, 6.7) 0.29 
 
 
Fasting insulin (μU/ml) 11.5 (8.0, 21.1) 13.9 (7.8, 19.4) 0.90 
 
120 min oral glucose tolerance 7.9 ± 2.2 7.5 ± 1.8 0.50 
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test (mmol/L)  
Alanine transaminase (iu/L) 56 (40, 73) 53 (30, 72) 0.38 
 
Aspartate aminotransferase 
(iu/L) 
41 (31, 54) 37 (27, 49) 0.15 
 
 
Weight (kg) 93.1 ± 14.6 98.7 ± 17.7 0.10 
 
Body mass index (kg/m
2
) 31.7 (28.7, 33.7) 32.8 (30.6, 37.4) 0.03 
 
Systolic blood pressure (mmHg) 138 ± 16 138 ± 17 0.86 
 
 
Diastolic blood pressure 
(mmHg) 
85 ± 8 85 ± 12 0.89 
 
 
CK-18 M65 (U/L) 605 (267, 792) 388 (245, 785) 0.28 
 
MRS Liver fat (%) 22.8 (13.7, 32.3) 23.3 (12.7, 47.5) 0.75 
 
Carotid IMT (mm) 0.674 ± 0.098 0.649 ± 0.095 0.21 
 
Presence of any carotid plaque 
(%) 
68.1 55.6 0.22 
 
 
Erythrocyte EPA (20:5n3) (%)  0.95 ± 0.39 0.89 ± 0.36 0.44 
 
 
Erythrocyte DHA (22:6n3) (%)  4.21 ± 1.49 3.87 ± 1.29 0.24 
 
 
 
Data are means ± standard deviation (SD), or median (25
th
, 75
th
 percentiles). 
Abbreviations: DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; CK-18 
M65, cytokeratin-18 M65 subfraction; MRS, magnetic resonance spectroscopy; IMT, 
intima-media thickness. 
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Baseline characteristics for the treatment and placebo groups were very similar, apart 
from the treatment group having higher baseline fasting serum triglyceride 
concentration (1.8 vs 1.4 mmol/L, p=0.03), and a higher baseline BMI (32.8 vs 31.7, 
p=0.03) compared to the control group. Liver fat, CK-18 and carotid IMT 
measurements were not significantly different between groups at baseline (Table 1), 
with mean carotid IMT of 0.674mm in the placebo group and 0.649mm in the 
treatment group (p=0.21). There was no significant change between baseline and end-
of-study statin and anti-hypertensive use between the two groups (data not shown). 
After 15-18 months of DHA+EPA treatment, carotid IMT in the treatment group 
progressed by 0.012mm (0.005, 0.020mm) or 1.7% (0.6, 3.2%), compared to 
0.015mm (0.007, 0.025mm) or 2.4% (0.9, 3.8%) in the placebo group (p=0.17). 
Furthermore, even in subjects with a >2% absolute erythrocyte DHA enrichment 
between baseline and end of study which has been shown to be significantly 
associated with liver fat reduction,
7
 there was no significant difference between 
carotid IMT percentage progression between the >2% DHA enrichment group (1.7% 
(0.6, 3.3%)) and the <2% DHA enrichment group (2.3% (0.9, 3.8%) (p=0.14). 
Importantly, there was also no significant difference in weight change between 
treatment and placebo groups over the 18 months (treatment, 0.62 ± 4.68 kg vs 
placebo, -0.17 ± 4.53 kg, p=0.42). 
We also examined changes (difference between end and baseline measurements) in all 
clinically relevant variables over the 18-month study period to evaluate univariate 
associations between these parameters and carotid IMT progression from baseline in 
the whole cohort. The correlation coefficients and p-values are presented in Table 2. 
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Table 2. Univariate associations between percentage carotid IMT progression 
and changes in relevant clinical variables between start and end of study (18 
months) in the entire cohort. 
 
 Correlation 
coefficient 
p-value 
 
 
Systolic blood pressure difference 
(mmHg) 
-0.12 0.26 
 
 
Diastolic blood pressure difference 
(mmHg) 
 
-0.04 0.69 
Weight difference (kg) 0.30 0.004 
Serum TG difference (mmol/L) 0.27 0.01 
 
 
Serum cholesterol difference (mmol/L) 0.23 0.03 
 
 
LDL-cholesterol difference (mmol/L) 0.14 0.26 
HDL-cholesterol difference (mmol/L) -0.06 0.55 
HOMA-IR % difference 0.22 0.08 
ALT difference (iu/L) 0.11 0.28 
AST difference (iu/L) 0.10 0.35 
EPA % change -0.05 0.64 
DHA % change -0.16 0.14 
CK-18 M65 difference (U/L) 0.27 0.009 
Liver fat difference (%) 0.49 <0.001 
 
Abbreviations: IMT, intima-media thickness; TG, triglycerides; LDL, low-density 
lipoprotein; HDL, high-density lipoprotein; HOMA-IR, homeostasis model 
assessment of insulin resistance; ALT, Alanine transaminase; AST, Aspartate 
aminotransferase; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; CK-18 
M65, cytokeratin-18 M65 subfraction. 
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Over the 18-month period, percentage carotid IMT progression was associated with 
an increase in weight among subjects (r=0.30, p=0.004), and inversely associated with 
differences in serum triglyceride (r=0.27, p=0.01) and total cholesterol concentrations 
(r=0.23, p=0.03). A decrease in liver fat percentage was strongly associated with 
reduced carotid IMT progression over 18 months (r=0.49, p<0.001) and change in 
CK-18 concentration was also positively correlated with carotid IMT progression 
(r=0.27, p=0.009) (Fig. 2). 
 
Figure 2. Scatter plot of relationship between carotid IMT percentage change 
and liver fat change (A) and CK-18 concentration change (B) between baseline 
and end of study in the entire cohort. 
 
When we also analysed the relationship between carotid IMT progression and the 
same clinical variables stratified by treatment group, we found similar associations. In 
the DHA+EPA group, reduced carotid IMT progression was significantly associated 
with liver fat decrease (r=0.52, p<0.001), CK-18 reduction (r=0.47, p=0.001), weight 
reduction (r=0.36, p=0.01) and decrease in cholesterol levels (r=0.34, p=0.03). In the 
placebo group, reduced carotid IMT progression was also significantly associated 
with liver fat decrease (r=0.43, p=0.004) and decrease in triglyceride levels (r=0.31, 
p=0.04), while decrease in weight only showed a trend toward reduced carotid IMT 
progression in the placebo group (p=0.06), as did reduced CK-18 levels (p=0.13). 
In multivariable linear regression analyses of the entire cohort, after adjusting for age, 
sex, diabetes, smoking, BMI, triglyceride concentration, statin and antihypertensive 
usage at baseline, as well as changes in weight and cholesterol concentration between 
A B
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the start and end of study, the only independent predictors of reduced carotid IMT 
progression over time were decreased liver fat (standardized β-coefficient 0.32, 
p=0.005), reduced CK-18 levels (standardized β-coefficient 0.22, p=0.04), as well as 
use of antihypertensive drugs at baseline (standardized β-coefficient -0.31, p=0.009). 
The overall model fit was R
2
 = 0.39 (Table 3). Weight change was not independently 
associated with carotid IMT progression over 18 months in the multivariate regression 
model (p=0.50). 
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Table 3. Associations between key explanatory variables and percentage carotid 
IMT difference between start and end of study (18 months) in the entire cohort 
 
Independent variables β-
coefficient 
Standardized 
β-coefficient 
95% CI for β-
coefficient 
p-
value 
 
Age 0.002 0.102 -0.003 to 0.008 0.39 
Sex 0.004 0.009 -0.097 to 0.105 0.94 
Diabetes  0.068 0.138 -0.036 to 0.173 0.20 
Smoking -0.002 -0.003 -0.143 to 0.139 0.98 
BMI at baseline <0.001 -0.011 -0.011 to 0.010 0.92 
Statin use at baseline 0.011 0.022 -0.091 to 0.113 0.84 
Antihypertensive use at 
baseline 
-0.150 -0.305 -0.261 to -0.038 0.009 
Weight difference (kg) 0.004 0.074 -0.008 to 0.016 0.50 
Serum total cholesterol 
difference (mmol/L) 
0.023 0.095 -0.027 to 0.074 0.37 
Serum TG difference 
(mmol/L) 
0.027 0.096 -0.035 to 0.088 0.39 
Liver fat difference (%) 0.006 0.321 0.002 to 0.010 0.005 
CK-18 M65 difference 
(U/L) 
<0.001 0.221 <0.001 to <0.001 0.04 
DHA % change -0.006 -0.048 -0.038 to 0.026 0.70 
 
Model fit R
2
 = 0.39 
Abbreviations: IMT, intima-media thickness; BMI, body mass index; TG, 
triglycerides; CK-18 M65, cytokeratin-18 M65 subfraction; DHA, docosahexaenoic 
acid 
(“Difference” or “change” variable represents the arithmetic difference between the 
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measurement at the end of study minus the baseline measurement for the independent 
variables included in the regression model). 
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As reported in the WELCOME study primary outcomes paper,
7
 liver fat percentage 
decreased in both the treatment and the placebo arms of the trial, between baseline 
and end of study. Although there was a greater reduction in liver fat percentage in the 
DHA+EPA group, this result was not statistically significant (active, -8.1% ± 17.4% 
vs placebo, -4.5% ± 9.2% (p=0.23). Consequently, we evaluated relevant putative 
univariate predictors of liver fat reduction across the entire study cohort and these are 
presented in Table 4 (supplementary appendix). 
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Table 4 (supplementary appendix). Univariate associations between percentage 
liver fat difference and changes in relevant putative aetiological variables 
between start and end of study (18 months) in the entire cohort. 
 
 Correlation 
coefficient 
p-value 
 
 
Systolic blood pressure difference 
(mmHg) 
 
-0.20 0.86 
 
Diastolic blood pressure difference 
(mmHg) 
 
0.003 0.98 
Weight difference (kg) 0.32 0.003 
 
Serum TG difference (mmol/L) 0.21 0.06 
 
 
Serum Cholesterol difference (mmol/L) 0.18 0.10 
 
 
LDL-cholesterol difference (mmol/L) 0.12 0.34 
 
HDL-cholesterol difference (mmol/L) -0.11 0.29 
 
HOMA-IR % difference 0.23 0.08 
 
EPA % change -0.09 0.41 
 
DHA % change -0.26 0.01 
 
Abbreviations: TG, triglycerides; LDL, low-density lipoprotein; HDL, high-density 
lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; EPA, 
eicosapentaenoic acid; DHA, docosahexaenoic acid. 
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Percentage liver fat change over the 18 months was significantly associated with 
weight change (r=0.32, p=0.003) as well as DHA percentage change (r=-0.26, 
p=0.01), and showed a non-significant trend towards an association with change in 
fasting serum triglyceride concentration (r=0.21, p=0.06) and homeostasis model 
assessment of insulin resistance (HOMA-IR) percentage change (r=0.23, p=0.08). 
When we tested factors that were associated with percentage liver fat change in the 
entire cohort with multivariable linear regression modelling, after adjusting for age, 
sex, baseline percentage liver fat, change in weight and DHA percentage change, only 
change in weight (standardized β-coefficient 0.30, p<0.001) and DHA percentage 
change (standardized β-coefficient -0.19, p=0.027) were still independently associated 
with liver fat change. The overall model fit was R
2
 = 0.48. Baseline percentage liver 
fat was also independently associated with liver fat change (standardized β-coefficient 
-0.53, p<0.001), which suggests that subjects with higher amounts of liver fat would 
have a larger absolute reduction in liver fat with increasing DHA enrichment or 
decrease in weight. 
  
Discussion 
 
This is the first study to document a novel association between an improvement in 
NAFLD severity, both in terms of markers of simple steatosis and steatohepatitis, and 
attenuation of carotid IMT progression during a randomized double-blind, placebo-
controlled trial.
7
 Although increased n-3 PUFA intake appears to be associated with 
reduced carotid atheroma burden in observational studies,
16
 our study did not show 
that high-dose n-3 PUFAs over 18 months had a significant independent beneficial 
effect on carotid IMT progression in subjects with NAFLD, even in those with 
significant increases in erythrocyte DHA levels compared to baseline. This lack of an 
effect of PUFA therapy is in contrast to the results of a recent cross sectional study of 
847 subjects by Dai et al., which showed that high erythrocyte DHA (but not EPA) 
concentrations were associated with decreased carotid IMT and plaque burden.
17
 Our 
findings are instead, consistent with a recent randomized study by Lonn et al., which 
showed that a much lower daily dose of n-3 PUFAs (1g) given to subjects with 
varying degrees of insulin resistance, had no favourable effect on carotid IMT 
progression compared to placebo.
18
 Consequently, although n-3 fatty acids have been 
reported to have several CV benefits including antithrombotic, anti-atherosclerotic 
and anti-inflammatory effects, as well as improvements in blood pressure and 
endothelial function,
19
 randomised trials have so far failed to show consistent benefits 
of n-3 PUFAs over placebo in reducing CV outcomes.
20
 One criticism of these studies 
has been that these trials tested too low doses of PUFA treatment. However, despite 
our study dose of 4g/day being the highest licensed dose for PUFA therapy, we did 
not find any benefit of n-3 PUFAs on carotid IMT progression compared to placebo.  
A previous systematic review reported a significant association between NAFLD and 
carotid IMT, showing an estimated increase of 13% in carotid IMT for patients with 
liver fat, compared to controls without liver fat.
21
 When we evaluated our entire 
cohort to investigate univariate associations between risk factors for CVD and carotid 
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IMT progression over 18 months, we found that changes in weight, serum triglyceride 
and total cholesterol concentration all had significant positive correlations with 
increased carotid IMT progression. This result is perhaps not unexpected given the 
strong association between lipid levels and the metabolic syndrome with carotid 
disease.
22
 However, and importantly, we also showed that a decrease in simple 
hepatic steatosis severity quantified by liver MRS as the gold-standard for non-
invasive assessment of liver fat percentage, was independently associated with 
reduced carotid IMT progression over 18 months; even after adjusting for all 
measured confounding factors including standard CV risk factors, weight change and 
relevant medication use (i.e. statins and antihypertensives), which are known to have 
an impact on carotid IMT progression.
23-26
 Furthermore, we found that changes in 
CK-18 levels from baseline to the end of study were also independently associated 
with carotid IMT progression after adjusting for the same confounding factors as 
above. As CK-18 levels have been shown to correlate well with histological features 
of hepatic inflammation and fibrosis, including its use for monitoring disease 
progression in NASH,
27-29
 our findings suggest that an improvement in steatohepatitis 
severity may also be independently associated with reduced carotid IMT progression. 
In a cross-sectional study, Targher et al. previously showed a progressive independent 
relationship between carotid IMT and increasing severity of NAFLD in 85 patients 
even after adjusting for classical CV risk factors and the metabolic syndrome.
30
 Our 
prospective, randomized-controlled trial confirms as well as extends that finding, 
showing that increasing severity of NAFLD is independently associated with carotid 
IMT progression over 18 months.  
Several observational and case-control studies have shown an increased incidence of 
adverse CV events in NAFLD subjects compared to the general population,
2
 with a 
higher rate of CV-related mortality in NASH compared to simple hepatic steatosis.
31, 
32
 The aetiology of increased CV risk appears to be multifactorial, with NAFLD 
acting as a pathological marker of ectopic fat accumulation, insulin resistance and 
low-grade systemic inflammation. These factors result in multiple deranged 
pathophysiological processes including abnormal metabolism of glucose, fatty acids 
and lipoproteins, worsening subclinical inflammation, increased oxidative stress, 
hypercoaguability, endothelial dysfunction and progression of atherosclerosis.
22, 33
 
These observations appear to be consistent with our finding of an association between 
a reduction in markers of NAFLD severity and decreased carotid IMT progression. 
When we also evaluated the potential causes of improvement in liver fat using 
multivariable linear regression modelling, we found that percentage DHA enrichment 
(either through dietary contamination in the placebo arm or good compliance with n-3 
PUFA in the treatment arm) and weight loss during the trial in the entire cohort were 
independently associated with improvements in liver fat. Thus, we reason that both 
these factors contributed to improvements in liver fat during the study. Although 
weight loss in obesity has been shown to significantly attenuate carotid IMT 
progression,
34-36
 we did not observe an independent association in our study after 
adjusting for relevant variables, including changes in NAFLD severity. Plausible 
explanations for this could be that our sample size was too small to detect a 
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difference, or that weight changes were not large enough to observe a response (i.e. 
more than 5% body weight
36
).  
There are limitations to our study. As this was a pre-specified sub-study of the 
WELCOME trial
11
 with carotid IMT progression as a key secondary outcome of the 
trial, we did not undertake sample size or power calculations to determine the 
appropriate number of participants necessary to test the effect of the intervention with 
respect to carotid IMT modification. Consequently, our study may have lacked 
sufficient power to prove that treatment with high dose DHA+EPA caused a decrease 
in carotid IMT progression. Furthermore, although we observed a significant 
independent association between two markers of NAFLD severity (liver fat 
percentage and CK-18 concentration) and carotid IMT progression, our study 
comprised relatively small numbers of participants, and we suggest that further larger 
studies are necessary to confirm these findings. Thirdly, although CK-18 can be used 
as a non-invasive marker of steatohepatitis, the gold-standard of quantifying liver 
inflammation and fibrosis would have been a liver biopsy. Due to concerns of the 
potential, albeit small, risk associated with serial liver biopsies, we did not consider 
invasive assessment of NALFD severity an appropriate component of our study 
methodology. Fourthly, the sensitivity of carotid IMT as a discriminatory measure is 
likely to vary widely among studies using different methodologies. However, we 
sought to minimize this by adhering to the recommended guidelines on the optimal 
measurement and reporting of carotid IMT studies.
15
 As a comparison, an analysis of 
the placebo groups from several large randomized placebo-controlled trials showed 
that the overall weighted rate of change in mean carotid IMT was 0.0147 mm/year,
4
 
which is higher than our placebo group estimated change of 0.010 mm/year. 
However, our cohort represents a lower CV risk population compared to most 
previous trial data, of which the majority encompass secondary prevention cohorts 
and this could consequently explain the smaller annual progression rate in our study. 
Finally, it is possible that 18 months of high-dose PUFA therapy is inadequate to 
observe a significant biological effect on carotid IMT progression. 
In conclusion, we have shown for the first time that an improvement in NAFLD 
severity over 18 months is associated with a beneficial effect on carotid IMT 
progression, a surrogate marker for cardiovascular outcomes.
3
 However, we observed 
no significant effect of the n-3 PUFA intervention over 18 months on carotid IMT 
progression.  Given that there is now increasing evidence that NAFLD portends a 
poorer CV outcome independent of several CV risk factors including the metabolic 
syndrome,
2
 and that worsening grades of NAFLD also contribute to progressive 
cardiometabolic risk, we suggest that further larger prospective studies should be 
performed to confirm these findings including the evaluation of other biomarkers of 
increased CV risk or adverse CV outcomes in NAFLD patients. Although lifestyle 
changes such as weight loss, increased exercise and reducing dietary fat intake are the 
only universally recommended therapeutic strategies with proven benefit to reduce 
NAFLD severity,
12
 and there are currently no established licensed pharmacological 
treatments for this disease, our findings of improved CIMT progression should 
encourage the ongoing trials of various therapeutic strategies, including active 
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lifestyle intervention, to reduce NAFLD severity,
37
 which may then ultimately confer 
improved CV outcomes in the NAFLD population. 
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